Navidea Biopharmaceuticals (NAVB) Competitors $0.0001 0.00 (0.00%) As of 09:30 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainSEC FilingsTrends NAVB vs. SCPS, EVLO, CMRA, GNCAQ, GNCA, ARDS, STAB, AMPE, CALA, and EFTRShould you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Calithera Biosciences (CALA), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Navidea Biopharmaceuticals vs. Scopus BioPharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals Calithera Biosciences eFFECTOR Therapeutics Scopus BioPharma (NASDAQ:SCPS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability. Do insiders & institutionals believe in SCPS or NAVB? 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community prefer SCPS or NAVB? Scopus BioPharma received 2 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 100.00% of users gave Scopus BioPharma an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo VotesNavidea BiopharmaceuticalsOutperform VotesNo VotesUnderperform Votes72100.00% Which has better valuation & earnings, SCPS or NAVB? Scopus BioPharma has higher earnings, but lower revenue than Navidea Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/ANavidea Biopharmaceuticals$70K0.14-$15.18MN/AN/A Does the media prefer SCPS or NAVB? In the previous week, Navidea Biopharmaceuticals had 1 more articles in the media than Scopus BioPharma. MarketBeat recorded 1 mentions for Navidea Biopharmaceuticals and 0 mentions for Scopus BioPharma. Scopus BioPharma's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Scopus BioPharma Neutral Navidea Biopharmaceuticals Neutral Is SCPS or NAVB more profitable? Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A Which has more risk and volatility, SCPS or NAVB? Scopus BioPharma has a beta of -0.21, suggesting that its stock price is 121% less volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. SummaryNavidea Biopharmaceuticals beats Scopus BioPharma on 5 of the 8 factors compared between the two stocks. Get Navidea Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAVB vs. The Competition Export to ExcelMetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$10,000.00$2.17B$5.39B$20.04BDividend YieldN/A0.66%5.37%3.61%P/E RatioN/A5.1788.8341.77Price / Sales0.1492.771,282.2617.54Price / CashN/A16.2336.6017.54Price / BookN/A3.434.965.86Net Income-$15.18M$29.98M$117.89M$1.01B7 Day PerformanceN/A1.21%2.75%3.59%1 Month PerformanceN/A-0.85%3.63%6.09%1 Year PerformanceN/A-16.08%27.27%20.27% Navidea Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-99.8%$10,000.00$70,000.000.0010Analyst ForecastNews CoverageSCPSScopus BioPharmaN/A$0.00flatN/A-91.4%$13,000.00N/A0.009High Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/A-99.1%$9,000.00N/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6,000.00$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.64M0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$5,000.00$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5,000.00$1.49M0.0020AMPEAmpio PharmaceuticalsN/A$0.00-97.0%N/A-99.8%$3,000.00N/A0.0020Analyst ForecastNews CoverageGap DownCALACalithera BiosciencesN/A$0.00flatN/A-99.4%$1,000.00$9.75M0.0060Analyst ForecastNews CoverageEFTReFFECTOR Therapeutics1.2303 of 5 stars$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010High Trading Volume Related Companies and Tools Related Companies Scopus BioPharma Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Ampio Pharmaceuticals Competitors Calithera Biosciences Competitors eFFECTOR Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NAVB) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NAVB Stock Alerts